Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519118 | 0.94 | KMT2A (0.42) | LMNAGAAMAPTCYP1A2CYP3A4 | |
| SCHEMBL6519419 | 0.89 | CTNNB1 (0.45) | LMNAGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL6516656 | 0.85 | GAA (0.49) | LMNAGAAMAPTCYP3A4KMT2A | |
| SCHEMBL6520891 | 0.84 | GAA (0.51) | LMNAGAAMAPTCYP3A4KMT2A | |
| SCHEMBL6519191 | 0.83 | SMN1; SMN2 (0.42) | LMNAGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL6514663 | 0.82 | SMN1; SMN2 (0.46) | LMNAMAPTKMT2AALDH1A1TDP1 | |
| SCHEMBL6522220 | 0.82 | KMT2A (0.45) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6519563 | 0.81 | NPC1 (0.53) | LMNAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL6514457 | 0.81 | NPC1 (0.53) | LMNAMAPTKMT2AALDH1A1TDP1 | |
| SCHEMBL6520666 | 0.81 | NPC1 (0.42) | LMNAMAPTCYP2C19KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958366-B2 | Antifouling coating composition and novel resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20030118544-A1 | Antifouling coating composition and novel resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118544-A1 | Antifouling coating composition and novel resin | COL1A1, GLRA1, COL2A1 | LMNA 2459/4885GAA 3231/4885MAPT 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.